SEC Form 4Coverage since Jun 1, 2026
$DGX insider trading
Over the last 12 months, Quest Diagnostics insiders reported no purchases and 3 sales totaling $3.9M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $3.9M 3 events
- Events · 12m
- 3 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $DGX · 12Mvia TradingView
Top insiders · 12m
DELANEY MARK ESVP & Chief Commercial Officer1× · $376K
KUPPUSAMY KARTHIKSVP, Clinical Solutions1× · $1.6M
Davis J. E.CEO and President1× · $1.9M
All insider trades
3 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | DELANEY MARK ESVP & Chief Commercial Officer · O | ▼ Sale | 1,600 | $235.18 | $376K | -13.4% | plan |
| Jun 4, 2026 | KUPPUSAMY KARTHIKSVP, Clinical Solutions · O | ▼ Sale | 8,147 | $200 | $1.6M | -37.6% | plan |
| Jun 1, 2026 | Davis J. E.CEO and President · O·D | ▼ Sale | 10,000 | $194.14 | $1.9M | -7% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $DGX feed.